Physician profile
Amy D Clemons
NPI 1225122435
$2,019.56
in general payments reported to CMS, 2019-2025
26 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $56.61 · 2021: $14.00 · 2022: $45.79 · 2023: $652 · 2024: $430 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.59 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $278.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $223.04 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $216.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $201.12 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $198.49 | 2019-2023 | Shingrix |
| Otsuka America Pharmaceutical, INC. | $197.18 | 2023-2025 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.32 | 2023 | Lifevest |
| Pfizer INC. | $102.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $82.78 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $63.62 | 2019 | |
| Abbott Laboratories | $42.44 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $37.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.45 | 2025 | Jardiance |
| Corcept Therapeutics | $24.38 | 2025 | Korlym |
| Philips North America LLC | $23.87 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.17 | 2024 | Rexulti |
| Bioventus LLC | $22.27 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.24 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $15.99 | 2024 | |
| Esperion Therapeutics, INC. | $14.51 | 2023 | Nexletol |
| Exact Sciences Corporation | $13.97 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $12.19 | 2019 | |
| Gilead Sciences, INC. | $11.79 | 2019 | |
| Merck Sharp & Dohme LLC | $11.19 | 2019 | |
| Avanir Pharmaceuticals, INC. | $10.99 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $7.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Clemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.